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and acute leukemia (OR = 3.4), end-stage liver disease
(OR = 2.8), renal failure (OR = 2.8), kidney transplant status
(OR = 2.8), severe hematological disorders (OR = 2.4), decubi-
tus ulcer of skin (OR = 1.9), congestive heart failure (OR = 1.9),
pancreatic disease (OR = 1.7), and major depressive/bipolar/
paranoid (OR = 1.7), peripheral vascular disease (OR = 1.6), and
type 1 diabetes (OR = 1.4). Age, gender, and type of insurance
were not signiﬁcantly related to high charges. CONCLUSION:
The most expensive DN patients spent over 50% of the total
charges. The comorbidities of DN patients incurred signiﬁcant
treatment charges. Managing comorbidities is important for
treating patients with DN.
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OBJECTIVE: Type 1 (T1D) and type 2 (T2D) diabetes are
serious and costly medical conditions. Complications related to
diabetes include diabetic neuropathy (DN), heart disease,
kidney disease, visual impairment, depression, and amputation.
Using claims data, we estimated the impact of T1D or any
other diabetes-related complications on health care charges and
utilization among DN patients. METHODS: Individuals who
were 18–64 years old and continuously enrolled in a large US
commercial plan between July 2004 and June 2006 were iden-
tiﬁed. The DN cohort was constructed by selecting patients
with at least 1 DN diagnosis anytime between July 2004 and
June 2005 (Year 1). We compared the prevalence of other
diabetes-related complications by type of diabetes (T1D vs.
T2D). Among DN patients with no or >/=1 other diabetes-
related complications, we used multivariate regressions to
assess the marginal contribution of T1D vs. T2D on Year 2
(July 2005 through June 2006) health care charges and utiliza-
tion. RESULTS: The majority of DN patients (7720 out of
8665) had >/=1 other diabetes-related complications, and T1D
accounted for 42% of the DN cohort. T1D patients had more
co-morbid medical conditions than patients with T2D (7.6 vs.
6.1 among patients with no other diabetes-related complica-
tions; 13.4 vs. 10.3 among those with >/=1 other diabetes-
related complications). The prevalence was higher for all other
diabetes-related complications, except heart disease, among
patients with T1D than patients with T2D. Controlling for
comorbidities, patients with T1D or T2D had similar health
care utilization among DN patients with no other diabetes-
related complications; however, patients with T1D had signiﬁ-
cantly higher total medical charges than patients with T2D
among those with >/=1 other diabetes-related complications.
CONCLUSION: Many DN patients have T1D and other
diabetes-related complications, which can have signiﬁcant
impact on health care charges and utilization.
PDB42
COST OF ILLNESS STUDY OFTYPE 2 DIABETES MELLITUS IN
LATIN AMERICA
Gonzalez JC1, Einarson TR2,Walker JH3
1Merck Sharp & Dohme, Bogota, Colombia, 2University of Toronto,
Toronto, ON, Canada, 3Brock University, Faculty of Business, St.
Catharines, ON, Canada
OBJECTIVE: We previously developed an incidence-based
Markov model to estimate the lifetime cost of type 2 diabetes
(T2DM) in Colombia. Here, we adapted it to seven other coun-
tries, representing almost 77.9% of Latin America. To estimate
the total direct and indirect lifetime costs of T2DM in Latin
America. METHODS: The model was adapted to each country
using country-speciﬁc epidemiologic rates and cost inputs. Due
to the lack of centralized databases in this region, purchase
power parity conversion factor was used. Costs in 2007 USD
(adjusted using the Consumer Price Index) and outcomes were
modeled over a 32-year time horizon using a 5% discount rate
for both. We calculated the direct, indirect, and total cost/
patient/year, then used epidemiological data to extrapolate to
all persons with T2DM in each country. Costs were summed
for the eight countries, then projected to Latin America, weigh-
ing by population estimates. RESULTS: Total direct costs for
Latin America were $22.8 billion, indirect costs were $46.9
billion, for a total of $69.7 billion for 2007. Colombia had the
lowest total cost/patient/year $847, although Venezuela had
lowest direct costs ($254 versus $288) and Peru had lowest
indirect costs ($547 versus $559); Mexico was highest ($1340/
patient/year); Brazil and Mexico were responsible for 63% of
direct and 62% of indirect costs in Latin America. These costs
differ from those estimated using a prevalence based model
(direct = $10.7, indirect = $54.5, total = $65.2 billion). CON-
CLUSION: This study presents new tools to estimate the cost
of illness for type 2 diabetes in Latin America. However, results
must be considered as rough estimates and validations are
required to verify them.
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OBJECTIVE: Tennessee residents face a heavy economic burden
of diabetes. Costs of hospitalization and treatment were $2.9
billion in 2003, with Tennessee ranking ﬁfth among the 50 states
in the prevalence of diagnosed diabetes. This study explores the
factors inﬂuencing these high inpatient and outpatient hospital
costs for patients with a primary diagnosis of diabetes in Ten-
nessee. We hypothesize that total charges will be most associated
with number or type of comorbidities, and also inﬂuenced by
race/ethnicity, source of admission, and type of insurance.
METHODS: This study utilized inpatient and outpatient ﬁles
from the 2003 Tennessee Hospital Discharge Data. Regression
models of log inpatient and outpatient charges were estimated
for all hospitalizations with a primary diagnosis of diabetes
(ICD-9 code: 250). RESULTS: As predicted, the most signiﬁcant
cost drivers were co-morbidities. A secondary diagnosis of dia-
betic ulcer added nearly $4800 to inpatient charges for diabetics,
and a diagnosis of heart failure contributed an additional $2000.
For outpatients, a secondary diagnosis of ﬂuid balance disorders
added $511 to total charges. Blacks, males, the elderly, and those
insured by managed care plans had signiﬁcantly higher inpatient
charges (all p < 0.01). In contrast, blacks, females, and those
with private insurance had signiﬁcantly higher outpatient charges
(all p < 0.01). CONCLUSION: To design strategies for decreas-
ing the high cost of diabetic treatment, it is critical to understand
the factors that induce increases in cost. The analysis revealed
that of the seven most frequent co-morbidities, ulcers contributed
most to the cost of diabetic hospitalizations. Complications of
diabetic ulcers may have necessitated further or longer treatment,
ultimately increasing charges. Thus, one strategy to reduce exces-
sive costs of treatment is to focus on ulcer prevention among
diabetics.
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